Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong healthcare momentum with multiple concrete catalysts: Q1 2026 revenue rose 56% to $19.8B, guidance was raised to $82B-$85B, Foundayo was FDA-approved and launched, PBM coverage expanded for obesity products, and Phase 3 data for retatrutide and Foundayo were strong.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Margins ⢠Rising Leverage ⢠Premium Valuation LLY's exceptional profitability and cash generation support growth, but rising leverage and premium valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support test ⢠Weak momentum Support Level: $1,148â$1,150; next $1,114â$1,120 Resistance Level: $1,173; stronger $1,190â$1,200 LLY fell 3.5% over the last month, with $1,148â$1,150 support critical; a break below risks $1,114â$1,120, while reclaiming $1,173 and then $1,190â$1,200 would signal improving momentum.
Sentiment & News
Key News Insights: ⢠Raised outlook ⢠Obesity leadership ⢠Pricing pressure Eli Lilly's surging obesity-drug demand and raised outlook support strong growth, though competitive pricing pressure and market-share plateauing remain key risks.
AI Summary
LLY is a high-expectations GLP-1 platform, not a defensive pharma stock: sustained upside requires Mounjaro/Zepbound to maintain pricing, share, and margins while retatrutide and oral Foundayo diversify the franchise; investors should avoid treating the recent pullback as a bargain until execution validates growth against rising competition, reimbursement pressure, and leverage.
Description
Eli Lilly and Company discovers, develops and commercializes prescription medicines worldwide, with established franchises in diabetes, oncology, immunology and central nervous system disorders. Its portfolio includes branded insulin and non-insulin therapies, oncology agents across multiple tumor types, treatments for autoimmune and psychiatric conditions, and respiratory and anti-infective products; the company also maintains collaborations with several biotech and pharmaceutical partners. Founded in 1876, Lilly is headquartered in Indianapolis and operates globally.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 1 | Jul 8 | LLY | Eli Lilly and Company | Strong healthcare momentum with multiple concrete catalysts: Q1 2026 revenue rose 56% to $19.8B, guidance was raised to $82B-$85B, Foundayo was FDA-approved and launched, PBM coverage expanded for obesity products, and Phase 3 data for retatrutide and Foundayo were strong. | Closed | +2.0% |
| Jun 16 | Jun 23 | LLY | Eli Lilly and Company | High-quality healthcare momentum with major earnings catalysts: Q1 2026 revenue rose 56% to $19.8B, full-year guidance was raised to $82B-$85B, and Mounjaro revenue grew 125% to $8.66B. Positive Phase 3 retatrutide results add pipeline support, with the stock up about 12% over 21 trading days. | Closed | -1.4% |
| Jun 8 | Jun 15 | LLY | Eli Lilly and Company | Strongest combination of fundamentals, catalysts, and momentum: Q1 2026 revenue rose 56%, adjusted EPS jumped 156%, guidance was raised, obesity portfolio access improved via major PBM coverage, Phase 3 retatrutide data were positive, and the stock is up about 22% over 21 trading days. | Closed | -1.7% |
| May 27 | Jun 3 | LLY | Eli Lilly and Company | Large-cap healthcare momentum with strong fundamentals: Q1 revenue grew 56% to $19.8B, full-year guidance was raised, Mounjaro and Zepbound demand remains strong, and recent FDA/pipeline/acquisition news keeps catalyst flow active. | Closed | -0.4% |
| May 12 | May 19 | LLY | Eli Lilly and Company | Healthcare selection with strong catalyst flow: Q1 2026 revenue rose 56%, management raised guidance, Foundayo received FDA approval and launched in the U.S., and positive Phase 3 data for retatrutide and Jaypirca add near-term pipeline support. | Closed | +3.4% |
| Feb 9 | Feb 16 | LLY | Eli Lilly and Company | High-quality growth stock with near-term catalysts including strong Q4 2025 revenue and EPS growth, positive Phase 3 data on weight-loss and oncology drugs, significant capital investments, and upcoming regulatory decisions. Technical signals indicate consolidation with steady momentum supporting tactical buying opportunities. | Closed | -0.3% |
| Jan 15 | Jan 22 | LLY | Eli Lilly and Company | Eli Lilly (LLY) is positioned for steady short-term growth with outstanding Q3 2025 earnings showing 54% revenue growth, strong free cash flow, and pipeline innovations including the upcoming launch of orforglipron. Strategic acquisitions and AI-powered partnerships augment its healthcare leadership. The stock shows moderate positive technical momentum, supporting its status as a hot idea amid healthcare innovation despite valuation caution. | Closed | +5.3% |